基于间充质基质细胞的胰腺癌靶向治疗：进展与挑战

Ma Zhilong, Hua Jie, Liu Jiang, Zhang Bo, Wang Wei, Yu Xianjun, Xu Jin

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong'An Road, Shanghai 200032, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Int J Mol Sci. 2023 Feb 10;24(4):3559. doi: 10.3390/ijms24043559.

Pancreatic cancer is an aggressive malignancy with high mortality rates and poor prognoses. Despite rapid progress in the diagnosis and treatment of pancreatic cancer, the efficacy of current therapeutic strategies remains limited. Hence, better alternative therapeutic options for treating pancreatic cancer need to be urgently explored. Mesenchymal stromal cells (MSCs) have recently received much attention as a potential therapy for pancreatic cancer owing to their tumor-homing properties. However, the specific antitumor effect of MSCs is still controversial. To this end, we aimed to focus on the potential anti-cancer treatment prospects of the MSC-based approach and summarize current challenges in the clinical application of MSCs to treat pancreatic cancer.

胰腺癌是一种侵袭性恶性肿瘤，死亡率高且预后差。尽管在胰腺癌的诊断和治疗方面取得了快速进展，但当前治疗策略的疗效仍然有限。因此，迫切需要探索更好的治疗胰腺癌的替代方案。间充质基质细胞（MSCs）因其肿瘤归巢特性，最近作为一种潜在的胰腺癌治疗方法受到了广泛关注。然而，MSCs的具体抗肿瘤作用仍存在争议。为此，我们旨在关注基于MSCs的方法的潜在抗癌治疗前景，并总结MSCs治疗胰腺癌临床应用中的当前挑战。